All Press Releases
Largest Phototherapy Trial for Parkinson’s Disease
Pivotal Trial Aims to Improve Overall Function and Quality of Life View on BusinessWire PhotoPharmics, a pioneer in specialized phototherapy for neurodegenerative diseases, alongside the Center for Health + Technology (CHeT) at the University of Rochester Medical...
Innovative Research, Inclusive Trials, and New Funding Drives Hope for People with Parkinson’s Disease
PhotoPharmics Secures $16 Million Investment Led by Kickstart to Fund Pivotal Clinical Trial for FDA Market Authorization PhotoPharmics, an innovator in Parkinson's disease research and treatment, today announced the successful first close of a $16 million investment...
Celeste® Light for PD Trial to be Presented at World Parkinson’s Congress
Celeste® Light for PD Trial to be Presented at World Parkinson’s Congress PhotoPharmics to showcase groundbreaking research at the prestigious international event July 5-7, 2023 PhotoPharmics, a leading innovator in Parkinson's disease, today announced that it will be...
PhotoPharmics to Present at MTI All Stars Investor Showcase
PhotoPharmics to Present at MTI All Stars Investor Showcase DeviceTalks in Boston on May 10-11 to feature pitches from PhotoPharmics and other leading startups PhotoPharmics today announced CEO Kent Savage has been invited to present at the inaugural MTI All Stars...
PhotoPharmics brings renowned experts in Parkinson’s disease and other neurodegenerative diseases to advisory board
View full press release on Businesswire. PhotoPharmics brings renowned experts in Parkinson’s disease and other neurodegenerative diseases to advisory board Breakthrough device innovator will leverage the expertise of leading authorities to bolster the company’s...
PhotoPharmics Appoints Dr. Karl Kieburtz as Chief Medical Officer
View full press release on Businesswire. PhotoPharmics Appoints Dr. Karl Kieburtz as Chief Medical Officer World-renowned neurologist and movement disorders specialist joins PhotoPharmics as company advances breakthrough device through pivotal clinical trial and to...
Utah-based PhotoPharmics Selected as Global Top 50 Startup
Utah-based PhotoPharmics Selected as Global Top 50 Startup MedTech Innovations designates PhotoPharmics as one of the industry’s best and brightest startups working to transform patient care through innovation June 24, 2021. Salt Lake City—PhotoPharmics today...
PhotoPharmics Innovations Address Global Health Inequalities
PhotoPharmics Innovations Address Global Health Inequalities Utah-based Life Sciences Company to Combine Breakthrough Designation and MCIT to Provide At-home Access for the Treatment of Neurodegenerative Diseases April 12, 2021, Salt Lake City, UT -- Innovation not...
Phase 3 Trial Aims to Establish Non-Motor Improvement in Parkinson’s
Phase 3 Trial Aims to Establish Non-Motor Improvement in Parkinson’s PhotoPharmics and University of Rochester to Collaborate on Stay-At-Home Trial July 14, 2020, Salt Lake City, UT— PhotoPharmics, a pioneer in specialized phototherapy for neurodegenerative diseases,...
FDA Grants Breakthrough Designation for Non-Invasive Phototherapy Device in Parkinson’s Disease
FDA Grants Breakthrough Designation for Non-Invasive Phototherapy Device in Parkinson’s Disease PhotoPharmics achieves priority designation for innovative PD therapy April 29, 2020, Salt Lake City, UT— PhotoPharmics, a pioneer in specialized phototherapy, today...
Media Contact
Brett Walker
801.770.6960
brett.walker@photopharmics.com